PALO ALTO, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative disorders, announced today that chairman and chief executive officer, Belinda Tsao Nivaggioli, Ph.D., will present an overview of the company's ongoing clinical development programs at the 10th Annual BIO CEO & Investor Conference to be held February 11-13, 2008 at the Waldorf Astoria Hotel in New York City. Dr. Tsao Nivaggioli will be presenting on Monday, February 11 at 12:30 p.m. (ET) in the East Foyer. For more information on this event please visit: http://ceo.bio.org/opencms/ceo/2008/about/index.jsp
To participate in a live audio webcast of Dr. Tsao Nivaggioli's presentation please log onto Avicena's corporate website at http://www.avicenagroup.com at least fifteen minutes prior to the start of the presentation to download any necessary materials. An archive of this event will be available in the investor relations section of the website for 90 days.
Avicena Group, Inc. (OTC Bulletin Board: AVGO) is a Palo Alto, California based late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative disorders. The company's core technologies, supported by a robust IP portfolio, have broad applications in both pharmaceuticals and dermaceuticals. Avicena's pharmaceutical program centers on rare neurological disorders (orphan diseases). Near term, the company plans to initiate a confirmatory Phase III trial in ALS and a Phase III trial in Huntington's disease to accompany the ongoing NIH Phase III trial in Parkinson's disease. Avicena's science is well established and its products are safe and well tolerated. Unlike traditional biotechnology companies, Avicena's clinical programs are largely funded by government and non-profit organizations. Avicena presently derives revenue from the sale of proprietary dermaceutical ingredients to skin care manufacturers.
This release contains forward-looking statements that reflect, among
other things, management's current expectations, plans and strategies, all
of which are subject to known and unknown risks, uncertainties and factors
that may cause our actual results to differ materially from those expressed
or implied by these forward-looking statements. Many of these risks are
beyond our ability to control or predict. See "Risk Factors" under "Item 6.
Management's Discussion and Analysis of Financial Condition and Results of
Operation" from our Annual Report on Form 10-KSB for the year ended
December 31, 2006, and other descriptions in the company's public filings
with the Securities and Exchange Commission for a discussion of such risks,
including the company's need for additional funds, the company's dependence
on a limited number of therapeutic compounds, the stage of the products the
company is developing, uncertainties relating to clinical trials and
regulatory reviews, competition and dependence on collaborative partners,
the company's ability to avoid infringement of the patent rights of others,
and the company's ability to obtain adequate patent protection and to
enforce these rights. Because of these risks, uncertainties and
assumptions, you should not place undue reliance on these forward-looking
statements. Furthermore, forward-looking statements speak only as of the
date they are made. Avicena does not undertake any obligation to update or
review any such forward-looking information, whether as a result of new
information, future events or otherwise.
The Ruth Group (on behalf of Avicena Group)
Sara Ephraim (investors)
Janine McCargo / Jason Rando (media)
(646) 536-7033 / 7025
|SOURCE Avicena Group, Inc.|
Copyright©2008 PR Newswire.
All rights reserved